Scholarlink

Background <p>Anxiety and depression are major global health concerns that can manifest as primary disorders or as comorbid symptoms alongside other medical conditions. Due to the troubling side effects and treatment resistance associated with conventional pharmacological interventions, therapeutic agents that target oxidative stress and inflammation, such as CoQ10, have been considered.</p> Objective <p>To quantitatively evaluate the effect of CoQ10 on symptoms of depression and anxiety across different clinical populations.</p> Methods <p>We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and comprehensively searched relevant databases up to March 2025. The primary outcomes were depression and anxiety symptoms measured by different validated scales. We estimated pooled effect estimates using standardized mean differences (SMDs) and applying random-effects models.</p> Results <p>We identified seven small trials with up to 400 patients meeting the eligibility criteria, of which six studies were included in the meta-analysis. CoQ10 demonstrated significant improvement in depression severity compared to placebo in trials using the Montgomery–Åsberg Depression Rating Scale (MADRS) 6–8 weeks after treatment initiation (3 trials, 158 patients, std. mean difference [95% CI] -0.97 [-1.49, -0.45]), and at low daily doses (3 trials, 193 patients, -0.84 [-1.54, -0.14]). No significant effects were observed in trials using the Beck Depression Inventory (BDI) (3 trials, 146 patients, -0.12 [-0.68, 0.43]). Regarding anxiety severity, only two small studies were analyzed, and no statistically significant reduction was observed with CoQ10 (101 patients, -0.28 [-0.70, 0.13]).</p> Conclusion <p>Our analysis provided limited evidence that CoQ10 may improve depressive symptoms when administered in low doses (100–200 mg/day) and for short durations (6–8 weeks). More data is needed for a reliable assessment of the effects of Coenzyme Q10 on both depression and anxiety.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of coenzyme Q10 supplementation on depressive symptoms and anxiety: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 发表日期：

    2025年8月20日

查看全文
  • Rami Akwan,
  • Muhammad M. Elsharkawy,
  • Azzam Zrineh,
  • Areen Amleh,
  • Bashar Douden,
  • Mays Alhouseini,
  • Layla Alsaeed,
  • Mohamed Eldesouki

摘要

Background

Anxiety and depression are major global health concerns that can manifest as primary disorders or as comorbid symptoms alongside other medical conditions. Due to the troubling side effects and treatment resistance associated with conventional pharmacological interventions, therapeutic agents that target oxidative stress and inflammation, such as CoQ10, have been considered.

Objective

To quantitatively evaluate the effect of CoQ10 on symptoms of depression and anxiety across different clinical populations.

Methods

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and comprehensively searched relevant databases up to March 2025. The primary outcomes were depression and anxiety symptoms measured by different validated scales. We estimated pooled effect estimates using standardized mean differences (SMDs) and applying random-effects models.

Results

We identified seven small trials with up to 400 patients meeting the eligibility criteria, of which six studies were included in the meta-analysis. CoQ10 demonstrated significant improvement in depression severity compared to placebo in trials using the Montgomery–Åsberg Depression Rating Scale (MADRS) 6–8 weeks after treatment initiation (3 trials, 158 patients, std. mean difference [95% CI] -0.97 [-1.49, -0.45]), and at low daily doses (3 trials, 193 patients, -0.84 [-1.54, -0.14]). No significant effects were observed in trials using the Beck Depression Inventory (BDI) (3 trials, 146 patients, -0.12 [-0.68, 0.43]). Regarding anxiety severity, only two small studies were analyzed, and no statistically significant reduction was observed with CoQ10 (101 patients, -0.28 [-0.70, 0.13]).

Conclusion

Our analysis provided limited evidence that CoQ10 may improve depressive symptoms when administered in low doses (100–200 mg/day) and for short durations (6–8 weeks). More data is needed for a reliable assessment of the effects of Coenzyme Q10 on both depression and anxiety.